E. Smith

发表

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Polymyositis as a Manifestation of Chronic Graft‐Versus‐Host Disease

A. Nademanee, J. Niland, J. Ben-Ezra, 1996, Medicine.

Management of chronic myeloid leukemia during pregnancy with leukapheresis

K. Voelkerding, F. Strobl, Eileen Smith, 1999, Journal of clinical apheresis.

PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

S. Kambhampati, T. Siddiqi, A. Salhotra, 2022, Clinical lymphoma, myeloma & leukemia.

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

A. Nademanee, J. Bading, J. Wong, 2021, Blood advances.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

A. Nademanee, J. Fridey, L. Weiss, 2007, Transfusion.

Hematologic disorders after solid organ transplantation.

E. Smith, 2010, Hematology. American Society of Hematology. Education Program.

Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.

A. Nademanee, M. Amylon, R. Negrin, 1994, Blood.

Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

A. Krishnan, S. Forman, C. Karanes, 2012, Leukemia & lymphoma.

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

A. Krishnan, S. Forman, D. Senitzer, 2010, Blood.

Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma

S. Howard, B. Flynn, J. Eickhoff, 2005, Leukemia & lymphoma.

Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease

Xiwei Wu, I. Aldoss, A. Salhotra, 2022, Bone Marrow Transplantation.

Developing and Monitoring a Standard of Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program.

S. Forman, D. Snyder, J. Rosenthal, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

A. Nademanee, S. Forman, J. Rosenthal, 2011, Annals of Hematology.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkin's Lymphoma (NHL)

David D. Smith, A. Nademanee, A. Krishnan, 2017 .

Non-Hodgkins Lymphoma (NHL) by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Combination with High-Dose Etoposide and Cyclophosphamide Followed A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2005, Blood.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tacrolimus and Sirolimus as GVHD Prophylaxis for Sibling Donor Hematopoietic Stem Cell Transplant (HCT) Using Three Conditioning Regimens; Fludarabine-Melphalan, FTBI-VP16, and Busulfan-Cyclophosphamide

S. Forman, D. Senitzer, D. Snyder, 2009 .

Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study

KyungMann Kim, H. Bailey, E. Williams, 2005, Cancer investigation.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Sonali M. Smith, J. Friedberg, L. Rimsza, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment

J. Richman, S. Bhatia, J. Wolfson, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

G. Marcucci, I. Aldoss, A. Salhotra, 2021, Blood.

A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa

R. Gangnon, B. Kahl, M. Juckett, 2004, Bone Marrow Transplantation.

Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

S. Forman, A. Artz, R. Spielberger, 2022, Bone Marrow Transplantation.

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.

A. Nademanee, G. M. Schmidt, D. Snyder, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

A. Nademanee, J. Niland, M. Amylon, 1993, The New England journal of medicine.

The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.

A. Nademanee, J. Niland, G. Somlo, 1995, Blood.

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.

J. Niland, G. Somlo, K. Margolin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission.

A. Nademanee, M. Amylon, R. Hoppe, 1991, Blood.

Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.

J. Niland, J. Ito, G. M. Schmidt, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD

K. Chang, S. Forman, D. Senitzer, 2010, Bone Marrow Transplantation.

Thalidomide as salvage therapy for chronic graft-versus-host disease.

J. Niland, R. Negrin, G. Somlo, 1995, Blood.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.

A. Nademanee, K. Margolin, G. M. Schmidt, 1992, Blood.

Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.

Y. Yen, L. Leong, P. Frankel, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

A. Nademanee, J. Niland, G. Somlo, 1997, Blood.

High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission

J. Niland, M. Slovak, D. Arber, 2000, Leukemia.